GO:1901188 negative regulation of ephrin receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901188 describes any process that stops, prevents or reduces the frequency, rate or extent of ephrin receptor signaling, a key cell-cell communication pathway.
• EPHB4-RASA1 is a canonical negative regulator that attenuates Ras-MAPK signaling downstream of ephrin receptors in the vasculature.
• Dysregulated ephrin receptor signaling contributes to vascular anomalies, cancer progression, and bone remodeling disorders [1,7,8].
• Ephrin receptors cross-talk with integrins and redox signaling, providing additional layers of negative regulation.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect negative regulatory nodes in this pathway [1,4,8].
• Targeting negative regulators such as RASA1 or EphB3 offers therapeutic potential for EPHB4/RASA1-related vascular anomalies and osteoporosis [1,8].
Description
The ephrin receptor signaling pathway is a critical mediator of cell-cell communication during development and tissue homeostasis. It is initiated by binding of ephrin ligands to Eph receptors, leading to receptor clustering, autophosphorylation, and downstream activation of Ras-MAPK, PI3K-AKT, and Rho GTPase cascades [1,6]. Unchecked ephrin signaling can drive pathological angiogenesis, tumor progression, and abnormal bone remodeling [1,7,8]. Therefore, negative regulation of ephrin receptor signaling (GO:1901188) is essential to maintain cellular and tissue homeostasis. This article synthesizes current knowledge on the mechanisms, key genes, and research methods for studying this regulatory process, with a focus on how CRISPR-based models can accelerate discovery [1,4,8].
negative regulation of ephrin receptor signaling pathway At A Glance
| GO ID | GO:1901188 |
|---|---|
| GO term | negative regulation of ephrin receptor signaling pathway |
| Ontology | biological_process |
| Synonym | inhibition of ephrin receptor signaling pathway; downregulation of Eph receptor signaling pathway |
| Major function | Attenuation of ephrin receptor signaling to prevent excessive downstream activation |
| Key regulators | RASA1, EphB4, EphB3, redox modulators, integrins |
| Associated diseases | Vascular anomalies, cancer, osteoporosis |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, phosphoproteomics, imaging |
What Is GO:1901188?
GO:1901188, negative regulation of ephrin receptor signaling pathway, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of ephrin receptor signaling. This includes mechanisms that directly inhibit Eph receptor activity, such as phosphatase-mediated dephosphorylation, or indirectly attenuate downstream signaling through negative feedback loops involving Ras GTPase-activating proteins like RASA1. The term encompasses both transcriptional and post-translational regulation that dampens ephrin receptor signaling output [1,3].
Why Is negative regulation of ephrin receptor signaling pathway Important in Cell Biology?
Negative regulation of ephrin receptor signaling is crucial for preventing aberrant activation of downstream pathways that drive disease. In the vasculature, EPHB4-RASA1-mediated negative regulation of Ras-MAPK signaling is essential for normal vessel development, and its disruption leads to vascular anomalies. In cancer, loss of negative regulation can enhance tumor cell proliferation and migration [2,7]. In bone, lack of EphB3 receptor, which may act as a negative regulator, prevents bone loss in osteoporosis models. Thus, understanding this process provides insights into disease mechanisms and therapeutic targets.
• Prevents excessive Ras-MAPK activation downstream of ephrin receptors.
• Maintains vascular homeostasis and prevents vascular anomalies.
• Modulates cancer cell proliferation and migration [2,7].
• Regulates bone remodeling and osteoporosis progression.
• Influences thymic development and immune cell interactions.
• Cross-talks with integrin signaling and redox regulation.
• Impacts glioma progression and potential therapies.
• Provides targets for CRISPR-based functional studies [1,4,8].
What Happens During negative regulation of ephrin receptor signaling pathway?
Receptor dephosphorylation and inactivation
In simple terms: Phosphatases remove phosphate groups from Eph receptors, turning off the signal.
Ephrin receptor activation requires autophosphorylation of tyrosine residues. Negative regulation can occur through protein tyrosine phosphatases that dephosphorylate these sites, thereby terminating downstream signaling. This mechanism is critical for resetting the pathway after ligand stimulation.
Ras-MAPK attenuation by RASA1
In simple terms: RASA1 acts as a brake on Ras, reducing MAPK signaling triggered by Eph receptors.
EPHB4 recruits RASA1 (p120 RasGAP) to the plasma membrane, where it inactivates Ras by promoting GTP hydrolysis, thus dampening MAPK signaling. This negative feedback loop is essential for vascular development and prevention of vascular anomalies.
Redox-dependent modulation of ephrin/integrin cross-talk
In simple terms: Oxidative stress can alter how ephrin receptors and integrins interact, affecting signaling.
Redox regulation influences ephrin/integrin cross-talk, with reactive oxygen species modulating the activity of these pathways. This provides an additional layer of negative regulation under oxidative conditions.
Feedback inhibition via Argonaute proteins and Insulin/IGF-1 signaling
In simple terms: Aging-related pathways can feedback to regulate ephrin signaling components.
Mutual regulation between spermatogenesis-specific Argonaute proteins and Insulin/IGF-1 signaling in aging control suggests a broader network where ephrin signaling may be indirectly negatively regulated. However, direct evidence for ephrin receptor regulation by this axis remains to be fully elucidated.
Key Genes Involved in GO:1901188 negative regulation of ephrin receptor signaling pathway
Key genes and proteins involved in negative regulation of ephrin receptor signaling include receptors, GTPase-activating proteins, phosphatases, and redox modulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EPHB4 | Receptor that recruits RASA1 to negatively regulate Ras-MAPK | Vascular anomalies, cancer |
| RASA1 | Ras GTPase-activating protein, negative regulator of Ras-MAPK | Vascular anomalies, cancer |
| EPHA2 | Ephrin receptor; its signaling can be negatively regulated by antisense RNA | Breast cancer proliferation/migration |
| EPHB3 | Receptor; lack prevents bone loss in osteoporosis models | Bone remodeling |
| EFNA1 | Ephrin ligand; interactions with receptors can be modulated | Thymus development |
| EFNB1 | Ephrin ligand; involved in thymic interactions | Thymus development |
| EFNB2 | Ephrin ligand; role in glioma | Glioma progression |
| EFNA5 | Ephrin ligand; role in glioma | Glioma progression |
| PTPN1 | Protein tyrosine phosphatase; may dephosphorylate Eph receptors | Negative regulation |
| PTPN11 | Phosphatase; potential negative regulator | Signaling attenuation |
| SRC | Kinase; can be regulated by redox and integrin cross-talk | Ephrin/integrin cross-talk |
| ITGB1 | Integrin; cross-talk with ephrin signaling | Redox regulation |
| MAPK8 | JNK1; downstream of EPHA2, can be negatively regulated | Breast cancer |
| MAPK9 | JNK2; downstream of EPHA2 | Breast cancer |
| NFATC2 | Transcription factor downstream of EPHA2 | Breast cancer |
| JUND | Transcription factor downstream of EPHA2 | Breast cancer |
| AGO | Argonaute proteins; mutual regulation with Insulin/IGF-1 signaling | Aging control |
How Is negative regulation of ephrin receptor signaling pathway Regulated?
Negative regulation of ephrin receptor signaling is itself regulated at multiple levels. RASA1 recruitment to EPHB4 is a key mechanism that attenuates Ras-MAPK signaling. Redox conditions modulate ephrin/integrin cross-talk, affecting the balance of positive and negative signals. Additionally, Insulin/IGF-1 signaling and Argonaute proteins exhibit mutual regulation that may influence ephrin pathway components during aging. These layers ensure tight control of ephrin receptor output.
negative regulation of ephrin receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EPHB4 | Vascular anomalies | Knockout mouse, endothelial cells |
| RASA1 | Vascular anomalies | Knockout mouse, patient-derived cells |
| EPHA2 | Breast cancer | MDA-MB-231 cells, xenograft |
| EPHB3 | Osteoporosis | Knockout mouse |
| EPHA2 | EBV-associated gastric cancer | Gastric cancer cell lines |
Vascular anomalies
Mutations in EPHB4 or RASA1 disrupt the negative regulation of Ras-MAPK signaling, leading to vascular anomalies such as capillary malformation-arteriovenous malformation. This highlights the importance of negative regulation in vascular homeostasis.
Cancer
In breast cancer, EPHA2 signaling promotes proliferation and migration, and its negative regulation by antisense RNA or other mechanisms can suppress these effects. In glioma, ephrin ligands and receptors are often dysregulated, and restoring negative regulation may offer therapeutic benefit.
Osteoporosis
Lack of EphB3 receptor prevents bone loss in mouse models of osteoporosis, suggesting that EphB3 may act as a negative regulator of bone formation or that its absence alters the balance of ephrin signaling.
EBV-associated gastric cancer
LMP2A regulates S901 phosphorylation of EphA2 to maintain EBV latent infection in gastric cancer, indicating that post-translational modifications of EphA2 can modulate its signaling and potentially its negative regulation.
From negative regulation of ephrin receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does RASA1 negatively regulate EPHB4 signaling? | RASA1 knockout endothelial cells |
| How does EPHA2 antisense RNA affect breast cancer? | EPHA2 overexpression/knockdown in MDA-MB-231 |
| Does EphB3 loss prevent bone loss? | EphB3 knockout mouse |
| How does LMP2A affect EphA2 phosphorylation? | Point mutation at S901 in gastric cancer cells |
| Does redox modulation affect ephrin/integrin cross-talk? | Integrin knockout cells under oxidative stress |
| What is the role of Argonaute proteins in aging? | Argonaute knockout models |
How to Study the negative regulation of ephrin receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Phosphorylation status of Eph receptors | Identify dephosphorylation events |
| CRISPR knockout screening | Gene knockouts that enhance signaling | Discover negative regulators |
| Live-cell imaging | Receptor clustering and internalization | Visualize negative regulation |
| RNA-seq | Transcriptional changes | Identify feedback regulators |
| Co-immunoprecipitation | Protein-protein interactions | Detect RASA1-EPHB4 binding |
| GTPase activity assay | Ras activity | Measure RASA1 function |
| Bone histomorphometry | Bone mass and remodeling | Assess EphB3 role in osteoporosis |
| Flow cytometry | Cell surface receptor levels | Quantify Eph receptor expression |
Phosphoproteomics
Phosphoproteomics can identify changes in Eph receptor phosphorylation upon negative regulation, revealing key sites and pathways [1,4].
CRISPR screening
Genome-wide CRISPR knockout screens can uncover novel negative regulators of ephrin receptor signaling by selecting for cells with enhanced pathway activity.
Live-cell imaging
Live-cell imaging of fluorescently tagged Eph receptors and downstream effectors can visualize the dynamics of negative regulation in real time [1,6].
RNA-seq and bioinformatics
RNA-seq combined with bioinformatics can identify transcriptional changes in ephrin pathway components and negative regulators under various conditions [2,7].
How CRISPR Can Be Used to Study GO:1901188 negative regulation of ephrin receptor signaling pathway
Knockout
CRISPR knockout of negative regulators such as RASA1 or EphB3 can lead to enhanced ephrin receptor signaling, providing models to study pathway hyperactivation and disease [1,8].
Point Mutation
Point mutations can be introduced to mimic phosphorylation sites or inactivate catalytic residues, e.g., S901 in EphA2, to dissect their role in negative regulation.
Knock-in
Knock-in of tagged versions of Eph receptors or regulators allows for live-cell imaging and proteomic analysis of negative regulation dynamics.
Overexpression
Overexpression of negative regulators like RASA1 can suppress ephrin receptor signaling, offering a strategy to validate their function and potential therapeutic effect.
How EDITGENE Supports negative regulation of ephrin receptor signaling pathway Research
Researchers studying negative regulation of ephrin receptor signaling-related genes often need to determine whether a candidate gene is causally involved in pathway attenuation or whether its manipulation alters disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of ephrin receptor signaling pathway research.
Frequently Asked Questions About negative regulation of ephrin receptor signaling pathway
What is GO:1901188?
GO:1901188 is the Gene Ontology term for negative regulation of ephrin receptor signaling pathway, describing processes that attenuate ephrin receptor signaling.
What genes are involved in negative regulation of ephrin receptor signaling?
Key genes include EPHB4, RASA1, EPHB3, and EPHA2, among others [1,2,8].
How does RASA1 negatively regulate ephrin receptor signaling?
RASA1 is recruited by EPHB4 to inactivate Ras, thereby dampening MAPK signaling downstream of ephrin receptors.
What diseases are associated with defective negative regulation of ephrin receptor signaling?
Vascular anomalies, cancer, and osteoporosis have been linked to disrupted negative regulation [1,2,8].
What research methods are used to study this pathway?
Phosphoproteomics, CRISPR screening, live-cell imaging, and RNA-seq are commonly used [1,2,7].
Can CRISPR be used to study negative regulation of ephrin receptor signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting this pathway [1,4,8].
What is the role of EphB3 in bone?
Lack of EphB3 prevents bone loss in osteoporosis models, suggesting it may negatively regulate bone formation.
How does redox regulation affect ephrin signaling?
Redox conditions modulate ephrin/integrin cross-talk, providing an additional layer of negative regulation.
What is the connection between ephrin signaling and cancer?
Dysregulated ephrin signaling promotes proliferation and migration in cancers such as breast cancer and glioma [2,7].
How can EDITGENE help my research on this pathway?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study negative regulation of ephrin receptor signaling [1,4,8].
Conclusion
Negative regulation of ephrin receptor signaling (GO:1901188) is a vital process that prevents excessive pathway activation and maintains tissue homeostasis. Key regulators such as RASA1 and EphB3 play critical roles in vascular and bone biology, and their dysfunction contributes to human diseases. CRISPR-based models are indispensable for dissecting these mechanisms and developing targeted therapies. EDITGENE offers a comprehensive suite of services to support such research.
References
- 1. Chen D et al.. 2023. EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans.. Pharmaceuticals (Basel) 16(2) PMID: 37259315
- 2. Odaka T et al.. 2024. Ephrin type-A receptor 2-antisense RNA1/2 promote proliferation and migration of MDA-MB-231 cells through EPHA2-dependent Ras signaling pathway mediated by MAPK8/JNK1, MAPK9/JNK2-NFATC2/NFAT1 and JUND.. Front Mol Biosci 11:1402354 PMID: 38855323
- 3. Buricchi F et al.. 2007. Redox regulation of ephrin/integrin cross-talk.. Cell Adh Migr 1(1):33-42 PMID: 19262085
- 4. Shi D et al.. 2025. LMP2A regulates S901 phosphorylation of EphA2 to maintain EBV latent infection in gastric cancer.. Br J Cancer 133(8):1085-1095 PMID: 40783630
- 5. Liontis T et al.. 2026. Mutual regulation of spermatogenesis-specific Argonaute proteins and Insulin/IGF-1 signaling in aging control.. EMBO Rep 27(6):1437-1462 PMID: 41507348
- 6. Muñoz JJ et al.. 2011. Eph/Ephrin-mediated interactions in the thymus.. Neuroimmunomodulation 18(5):271-80 PMID: 21952679
- 7. Zhu B et al.. 2022. A review on the role of different ephrins in glioma.. Eur J Pharmacol 917:174588 PMID: 34688637
- 8. Rodríguez-Sosa MR et al.. 2024. The lack of EphB3 receptor prevents bone loss in mouse models of osteoporosis.. J Bone Miner Res 39(7):1008-1024 PMID: 38739682
